An Inexpensive, Point‐of‐Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation

• DOI: 10.1002/adhm.201700808
• Publication Date: 2017-09-08T12:46:40Z
• Authors: Abhinav P. Acharya; Kathryn M. Theisen; Andres Correa; Thiagarajan Meyya...; Abraham Apfel; Tao Sun; Tatum V. Tarin; Steven R. Little
• Keywords: Male; Point-of-Care Systems; Pilot Projects; Middle Aged; Sensitivity and Specificity; 6. Clean water; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Molecular Diagnostic Techniques; Urinary Bladder Neoplasms; Humans; Female; Hematuria

AbstractAlthough hematuria (blood in urine) is the most common symptom of bladder cancer, 70–98% of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office‐based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases (“Ammps”) is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin‐conjugated alginate (Fe(II)) nanoparticles by collagenases generates free‐floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100% sensitivity, 85% specificity, and a negative predictive value (NPV) of 100% for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.